TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07250269: A Phase 1b Study of GC012F, a Chimeric Antigen Receptor T Cell Therapy Targeting CD19 and B-cell Maturation Antigen in Chinese Participants With Relapsed or Refractory AL Amyloidosis

Sponsor: Gracell Biotechnologies (Shanghai) Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$270,912

Rescue Site Savings

+$180,608

Unlock Full NCT07250269 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07250269 Rescue Dossier →